- Home
- LUNG vs KYTX Comparison
LUNG vs KYTX Comparison
Compare LUNG & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- KYTX
- Stock Information
- Founded
- LUNG 1995
- KYTX 2018
- Country
- LUNG United States
- KYTX United States
- Employees
- LUNG N/A
- KYTX N/A
- Industry
- LUNG Industrial Specialties
- KYTX
- Sector
- LUNG Health Care
- KYTX
- Exchange
- LUNG Nasdaq
- KYTX NYSE
- Market Cap
- LUNG 248.0M
- KYTX 290.8M
- IPO Year
- LUNG 2020
- KYTX 2024
- Fundamental
- Price
- LUNG $7.30
- KYTX $4.63
- Analyst Decision
- LUNG Strong Buy
- KYTX Buy
- Analyst Count
- LUNG 7
- KYTX 3
- Target Price
- LUNG $13.71
- KYTX $26.67
- AVG Volume (30 Days)
- LUNG 237.6K
- KYTX 422.2K
- Earning Date
- LUNG 10-28-2024
- KYTX 11-12-2024
- Dividend Yield
- LUNG N/A
- KYTX N/A
- EPS Growth
- LUNG N/A
- KYTX N/A
- EPS
- LUNG N/A
- KYTX N/A
- Revenue
- LUNG $76,583,000.00
- KYTX N/A
- Revenue This Year
- LUNG $22.73
- KYTX N/A
- Revenue Next Year
- LUNG $19.02
- KYTX N/A
- P/E Ratio
- LUNG N/A
- KYTX N/A
- Revenue Growth
- LUNG 26.26
- KYTX N/A
- 52 Week Low
- LUNG $5.46
- KYTX $4.51
- 52 Week High
- LUNG $14.84
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- LUNG 41.60
- KYTX 23.25
- Support Level
- LUNG $7.18
- KYTX $4.53
- Resistance Level
- LUNG $8.59
- KYTX $4.98
- Average True Range (ATR)
- LUNG 0.40
- KYTX 0.44
- MACD
- LUNG -0.16
- KYTX -0.12
- Stochastic Oscillator
- LUNG 7.74
- KYTX 4.23
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.